AZTR — Azitra Inc Common Stock
Session close: $1.53. Regular-session share volume: 138,525,325.
Key developments
Azitra announced progress in its cosmetic protein program targeting the appearance of fine lines and wrinkles. The report's headline describes ex vivo findings in human skin showing reduced fine lines and improved elasticity, providing a potentially favorable development for the company's cosmetic pipeline.
The announcement came before the trading session and said Azitra's cofounder and chief operating officer would present detailed data at BIO-Europe in Cologne. The supplied excerpt contains no detailed study results or clinical evidence in patients, limiting assessment of the findings. The presentation date lacks an explicit year.
News sources
Company news Azitra Shares Halted On Circuit Breaker To The Upside, Stock Now Up 126.47% · Company news Azitra Suspends ATM Offering Program For The Foreseeable Future; From September 28, 2026 - October 26, 2026, The Company Sold An Aggregate Of 1,000 Shares Of Common Stock Under The ATM Program For Aggregate Gross Proceeds Of ~$126 · Company news Azitra To Present Progress For Its Cosmetic ATR-COSF Program Targeting Fine Lines And Wrinkles At Bio-europe, November 10; First-In-Human Study With ATR-COSF Initial Results Anticipated By End Of 2026 · Company news Azitra, Inc. Announces Revitalizing Results from Ex Vivo Study of ATR-COSF Demonstrating Ability to Reduce Fine Lines and Improve Elasticity in Human Skin